Artificial intelligence-derived gut microbiome as a predictive biomarker for therapeutic response to immunotherapy in lung cancer - Trial UMIN000051705
Access comprehensive clinical trial information for UMIN000051705 through Pure Global AI's free database. This phase not specified trial is sponsored by National Hospital Organization and is currently Not yet recruiting. The study focuses on Lung cancer.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to University Hospital Medical Information Network data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
UMIN000051705
Not yet recruiting
Trial Details
University Hospital Medical Information Network • UMIN000051705
Artificial intelligence-derived gut microbiome as a predictive biomarker for therapeutic response to immunotherapy in lung cancer
Study Focus
Observational
Sponsor & Location
National Hospital Organization
Japan
Timeline & Enrollment
N/A
Sep 30, 2023
N/A
ICD-10 Classifications
Carcinoma in situ: Bronchus and lung
Secondary malignant neoplasm of lung
Malignant neoplasm of bronchus and lung
Malignant neoplasm: Bronchus or lung, unspecified
Malignant neoplasm: Overlapping lesion of bronchus and lung
Data Source
University Hospital Medical Information Network
UMIN000051705
Non-Device Trial